TY - JOUR
T1 - In vivo CART cell imaging
T2 - Paving the way for success in CART cell therapy
AU - Sakemura, Reona
AU - Can, Ismail
AU - Siegler, Elizabeth L.
AU - Kenderian, Saad S.
N1 - Funding Information:
This work was partly supported through the Mayo Clinic K2R Pipeline (to S.S.K.), the Mayo Clinic Center for Individualized Medicine (to S.S.K.), and the Henry J. Predolin Foundation (to R.S.). We thank Dr. Kah-Whye Peng for providing the images used in Figure 2 .
Funding Information:
S.S.K. is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between the Mayo Clinic, University of Pennsylvania, and Novartis) and to Mettaforge (through the Mayo Clinic). R.S. and S.S.K. are inventors on patents in the field of CAR immunotherapy that are licensed to Humanigen. S.S.K. receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs, and Lentigen.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/3/26
Y1 - 2021/3/26
N2 - Chimeric antigen receptor T (CART) cells are a promising immunotherapy that has induced dramatic anti-tumor responses in certain B cell malignancies. However, CART cell expansion and trafficking are often insufficient to yield long-term remissions, and serious toxicities can arise after CART cell administration. Visualizing CART cell expansion and trafficking in patients can detect an inadequate CART cell response or serve as an early warning for toxicity development, allowing CART cell treatment to be tailored accordingly to maximize therapeutic benefits. To this end, various imaging platforms are being developed to track CART cells in vivo, including nonspecific strategies to image activated T cells and reporter systems to specifically detect engineered T cells. Many of these platforms are clinically applicable and hold promise to provide valuable information and guide improved CART cell treatment.
AB - Chimeric antigen receptor T (CART) cells are a promising immunotherapy that has induced dramatic anti-tumor responses in certain B cell malignancies. However, CART cell expansion and trafficking are often insufficient to yield long-term remissions, and serious toxicities can arise after CART cell administration. Visualizing CART cell expansion and trafficking in patients can detect an inadequate CART cell response or serve as an early warning for toxicity development, allowing CART cell treatment to be tailored accordingly to maximize therapeutic benefits. To this end, various imaging platforms are being developed to track CART cells in vivo, including nonspecific strategies to image activated T cells and reporter systems to specifically detect engineered T cells. Many of these platforms are clinically applicable and hold promise to provide valuable information and guide improved CART cell treatment.
UR - http://www.scopus.com/inward/record.url?scp=85102562442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102562442&partnerID=8YFLogxK
U2 - 10.1016/j.omto.2021.03.003
DO - 10.1016/j.omto.2021.03.003
M3 - Review article
AN - SCOPUS:85102562442
SN - 2372-7705
VL - 20
SP - 625
EP - 633
JO - Molecular Therapy - Oncolytics
JF - Molecular Therapy - Oncolytics
ER -